Interpace Diagnostics shares are also trading higher after Ampersand Capital Partners agreed to invest $27 million in the company in two tranches of newly issued convertible preferred stock.
Cancer Genetics shares are up 53% at 27 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.30 and a 52-week low of 15 cents per share.
Interpace Diagnostics shares are up 3.8% at 72 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.78 and a 52-week low of 67 cents per share.
JPMorgan Q2 Earnings Beat Estimates
Johnson & Johnson Trades Higher On Q2 Earnings Beat
See more from Benzinga
- Prologis Buys Black Creek's Platform For .9B
- Wells Fargo Reports Q2 Earnings Beat
- Goldman Sachs Reports Q2 Earnings Beat
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.